162 related articles for article (PubMed ID: 30280391)
1. Monitoring Early Breast Cancer Response to Neoadjuvant Therapy Using H-Scan Ultrasound Imaging: Preliminary Preclinical Results.
Khairalseed M; Javed K; Jashkaran G; Kim JW; Parker KJ; Hoyt K
J Ultrasound Med; 2019 May; 38(5):1259-1268. PubMed ID: 30280391
[TBL] [Abstract][Full Text] [Related]
2. Three-Dimensional H-Scan Ultrasound Imaging of Early Breast Cancer Response to Neoadjuvant Therapy in a Murine Model.
Tai H; Song J; Li J; Reddy S; Khairalseed M; Hoyt K
Invest Radiol; 2022 Apr; 57(4):222-232. PubMed ID: 34652291
[TBL] [Abstract][Full Text] [Related]
3. H-Scan Ultrasound Monitoring of Breast Cancer Response to Chemotherapy and Validation With Diffusion-Weighted Magnetic Resonance Imaging.
Tai H; Margolis R; Li J; Hoyt K
J Ultrasound Med; 2023 Jun; 42(6):1297-1306. PubMed ID: 36468546
[TBL] [Abstract][Full Text] [Related]
4. High-Resolution Ultrasound Characterization of Local Scattering in Cancer Tissue.
Khairalseed M; Hoyt K
Ultrasound Med Biol; 2023 Apr; 49(4):951-960. PubMed ID: 36681609
[TBL] [Abstract][Full Text] [Related]
5. Spatial Angular Compounding Technique for H-Scan Ultrasound Imaging.
Khairalseed M; Xiong F; Kim JW; Mattrey RF; Parker KJ; Hoyt K
Ultrasound Med Biol; 2018 Jan; 44(1):267-277. PubMed ID: 29031985
[TBL] [Abstract][Full Text] [Related]
6. Real-time H-scan ultrasound imaging using a Verasonics research scanner.
Khairalseed M; Brown K; Parker KJ; Hoyt K
Ultrasonics; 2019 Apr; 94():28-36. PubMed ID: 30606648
[TBL] [Abstract][Full Text] [Related]
7. 3-D H-Scan Ultrasound Imaging and Use of a Convolutional Neural Network for Scatterer Size Estimation.
Tai H; Khairalseed M; Hoyt K
Ultrasound Med Biol; 2020 Oct; 46(10):2810-2818. PubMed ID: 32653207
[TBL] [Abstract][Full Text] [Related]
8. 3-D H-scan ultrasound imaging of relative scatterer size using a matrix array transducer and sparse random aperture compounding.
Tai H; Basavarajappa L; Hoyt K
Comput Biol Med; 2022 Dec; 151(Pt B):106316. PubMed ID: 36442278
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer.
Chakravarthy AB; Kelley MC; McLaren B; Truica CI; Billheimer D; Mayer IA; Grau AM; Johnson DH; Simpson JF; Beauchamp RD; Jones C; Pietenpol JA
Clin Cancer Res; 2006 Mar; 12(5):1570-6. PubMed ID: 16533783
[TBL] [Abstract][Full Text] [Related]
11. Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy.
Saracco A; Szabó BK; Tánczos E; Bergh J; Hatschek T
Acta Radiol; 2017 Apr; 58(4):394-402. PubMed ID: 27461224
[TBL] [Abstract][Full Text] [Related]
12. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
Cheung YC; Chen SC; Su MY; See LC; Hsueh S; Chang HK; Lin YC; Tsai CS
Breast Cancer Res Treat; 2003 Mar; 78(1):51-8. PubMed ID: 12611457
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.
Symmans WF; Volm MD; Shapiro RL; Perkins AB; Kim AY; Demaria S; Yee HT; McMullen H; Oratz R; Klein P; Formenti SC; Muggia F
Clin Cancer Res; 2000 Dec; 6(12):4610-7. PubMed ID: 11156210
[TBL] [Abstract][Full Text] [Related]
14. Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET.
Hsueh WA; Kesner AL; Gangloff A; Pegram MD; Beryt M; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2006 Dec; 47(12):1995-9. PubMed ID: 17138742
[TBL] [Abstract][Full Text] [Related]
15. Time course of Paclitaxel-induced apoptosis in an experimental model of virus-induced breast cancer.
Erba PA; Manfredi C; Lazzeri E; Minichilli F; Pauwels EK; Sbrana A; Strauss HW; Mariani G
J Nucl Med; 2010 May; 51(5):775-81. PubMed ID: 20395330
[TBL] [Abstract][Full Text] [Related]
16. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.
Demaria S; Volm MD; Shapiro RL; Yee HT; Oratz R; Formenti SC; Muggia F; Symmans WF
Clin Cancer Res; 2001 Oct; 7(10):3025-30. PubMed ID: 11595690
[TBL] [Abstract][Full Text] [Related]
17. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer.
Chappuis PO; Goffin J; Wong N; Perret C; Ghadirian P; Tonin PN; Foulkes WD
J Med Genet; 2002 Aug; 39(8):608-10. PubMed ID: 12161606
[No Abstract] [Full Text] [Related]
18. Volumetric contrast-enhanced ultrasound imaging to assess early response to apoptosis-inducing anti-death receptor 5 antibody therapy in a breast cancer animal model.
Hoyt K; Sorace A; Saini R
J Ultrasound Med; 2012 Nov; 31(11):1759-66. PubMed ID: 23091246
[TBL] [Abstract][Full Text] [Related]
19. Using Flow Characteristics in Three-Dimensional Power Doppler Ultrasound Imaging to Predict Complete Responses in Patients Undergoing Neoadjuvant Chemotherapy.
Shia WC; Huang YL; Wu HK; Chen DR
J Ultrasound Med; 2017 May; 36(5):887-900. PubMed ID: 28109009
[TBL] [Abstract][Full Text] [Related]
20. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
